“Recent market volatility driven by fears of AI disruption is presenting attractive buying opportunities for investors. While concerns focus on potential job losses and sector upheaval, only about 13% of the S&P 500 market cap faces significant vulnerability. These at-risk areas are trading at historically cheap valuations, remain under-owned by investors, and often exhibit strong … Read more
**” In a market where alignment between management and shareholders often signals strong future performance, several global companies stand out with forecasted earnings growth around or exceeding 81% alongside substantial insider ownership. These firms, spanning technology, energy, consumer sectors, and more, demonstrate insider confidence through significant stakes, potentially positioning them for outperformance amid economic uncertainties. … Read more
“Intellia Therapeutics has surged 41% year-to-date amid FDA clearance to resume a key Phase 3 trial for its CRISPR-based therapy targeting hereditary ATTR amyloidosis with polyneuropathy, positioning the company as a frontrunner in gene editing innovation. However, ongoing clinical risks, high cash burn rates, and competition from established treatments raise questions about its long-term viability … Read more